SVB Leerink began coverage on shares of Sanofi (NASDAQ:SNY – Get Rating) in a research note issued to investors on Monday, The Fly reports. The brokerage issued an outperform rating on the stock. SVB Leerink also issued estimates for Sanofi’s Q1 2023 earnings at $1.02 EPS, Q1 2023 earnings at $1.02 EPS, Q2 2023 earnings at $0.94 EPS, Q2 2023 earnings at $0.94 EPS, Q3 2023 earnings at $1.32 EPS, Q3 2023 earnings at $1.32 EPS, Q4 2023 earnings at $0.97 EPS and Q4 2023 earnings at $0.97 EPS.
Several other brokerages have also commented on SNY. Barclays raised their price objective on Sanofi from €90.00 ($95.74) to €105.00 ($111.70) in a report on Thursday, April 14th. Stifel Nicolaus started coverage on Sanofi in a report on Monday, February 28th. They issued a buy rating on the stock. Liberum Capital raised Sanofi from a hold rating to a buy rating in a research note on Tuesday, January 25th. Morgan Stanley lifted their price target on Sanofi from €110.00 ($117.02) to €112.00 ($119.15) in a research note on Friday, April 22nd. Finally, Guggenheim lifted their price target on Sanofi from €121.00 ($128.72) to €127.00 ($135.11) in a research note on Monday, May 2nd. One investment analyst has rated the stock with a sell rating and seven have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of Buy and an average target price of $99.86.
Shares of SNY opened at $55.85 on Monday. The company has a current ratio of 1.44, a quick ratio of 1.03 and a debt-to-equity ratio of 0.25. Sanofi has a 12 month low of $46.92 and a 12 month high of $58.10. The stock’s 50 day moving average is $53.33 and its two-hundred day moving average is $51.63. The firm has a market cap of $141.15 billion, a P/E ratio of 18.07, a PEG ratio of 1.09 and a beta of 0.50.
A number of institutional investors have recently made changes to their positions in SNY. GHP Investment Advisors Inc. purchased a new stake in Sanofi in the first quarter valued at $26,000. Fairfield Bush & CO. purchased a new stake in Sanofi in the first quarter valued at $26,000. First Community Trust NA purchased a new stake in Sanofi in the fourth quarter valued at $26,000. Pinnacle Bancorp Inc. raised its position in Sanofi by 49.0% in the first quarter. Pinnacle Bancorp Inc. now owns 587 shares of the company’s stock valued at $30,000 after purchasing an additional 193 shares during the period. Finally, Ahrens Investment Partners LLC purchased a new stake in Sanofi in the first quarter valued at $31,000. Hedge funds and other institutional investors own 12.82% of the company’s stock.
About Sanofi (Get Rating)
Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products.
- Get a free copy of the StockNews.com research report on Sanofi (SNY)
- Is Zoom Video (NASDAQ: ZM) Starting To Bottom Out?
- Short-Covering Begins In Big Lots
- Institutions Ring The Register On Toll Brothers Stock
- Agilent Technologies Is Bottoming But Don’t Buy It Yet
- Dick’s Sporting Goods Falls Flat On Weak Guidance
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.